We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients

By LabMedica International staff writers
Posted on 24 Jul 2022

Doctors typically measure hematocrit and globulins (difference between total protein and albumin) in all patients for diagnosis and monitoring treatment of hospitalized COVID-19 patients; however, they do not measure blood viscosity directly. More...

A validated estimate of blood viscosity can be derived from the hematocrit and globulins. Now, a new study has found that the estimate of blood viscosity was more strongly associated with mortality in COVID-19 patients than other commonly used risk stratification measures. This is an easy calculation that could be added to electronic medical records or lab forms and can improve chances for survival in hospitalized COVID-19 patients.

The large-scale study by researchers at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) is the first to evaluate blood viscosity in the prediction of mortality in COVID-19 patients. The researchers looked at records of 5,621 COVID-19 patients from six hospitals in the Mount Sinai Health System between February 27, 2020, and November 27, 2021. All had clinical and laboratory-verified diagnoses of COVID 19 and were identified within 48 hours of hospitalization and followed until hospital discharge or death. The study found that hospitalized patients who had high blood viscosity had a 60% higher death rate with blood viscosity measured under high flow conditions such as the arteries and 32% higher mortality with blood viscosity measured at low flow such as the microcirculation (blood circulation in the smallest vessels), than patients with a low blood viscosity.

Blood viscosity is elevated by acute phase reactants (fibrinogen, macroglobulins) that have been associated with acute COVID-19 infections. Blood viscosity is an integrated measure of these acute phase reactants and the cellular components that can increase during infection. When the blood viscosity is high, physicians may consider therapeutic heparin for patients, hydration, or intensification of glucocorticoids to lessen the severity of the acute phase response to COVID-19. The study concluded that that a simple calculation of blood viscosity was more robust in the identification of hospitalized patients at risk for dying from COVID-19 complications when compared to common measures of inflammation and the blood clotting biomarker D-dimer.

“This study demonstrates the importance of checking for blood viscosity in COVID-19 patients early in hospital admission, which is easily obtained through routine lab work. Results can help determine the best treatment course for at-risk patients and help improve outcomes,” said Robert Rosenson, MD, Professor of Medicine (Cardiology) at the Icahn School of Medicine at Mount Sinai. “We are currently investigating the effects of therapeutic heparin to reduce the risk of complications during acute COVID-19 infections, which may greatly benefit those with high blood viscosity.”

Related Links:
Icahn School of Medicine at Mount Sinai 


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Specimen Radiography System
TrueView 200 Pro
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.